Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) Read more about Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Read more about A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer Read more about Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Read more about Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials Read more about Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors Read more about A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial Read more about Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Read more about Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
National Cancer Institute "Cancer Moonshot Biobank" Read more about National Cancer Institute "Cancer Moonshot Biobank"
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors Read more about Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors